Feliqs

Feliqs is a biotechnology company developing first-class small-molecule therapies targeting oxidized lipids for the treatment of rare pediatric retinal diseases, utilizing a unique drug discovery platform focused on oxidized lipids to address unmet medical needs in ophthalmology. The company’s lead project, FLQ-101, aims to prevent retinopathy of prematurity, a potentially blinding disease affecting premature infants. FELIQS Corporation is advancing clinical research in the United States.